Brief: Xencor Presents Updated Data From Phase 1 Study Of Vudalimab, PD-1 X CTLA-4 Bispecific Antibody

Xencor

12/11/2021 12:18

Nov 12 (Reuters) - Xencor Inc  XNCR.O :
    * XENCOR PRESENTS UPDATED DATA FROM THE PHASE 1 STUDY OF
VUDALIMAB, PD-1 X CTLA-4 BISPECIFIC ANTIBODY, AT THE SITC ANNUAL
MEETING
    * XENCOR INC - VUDALIMAB WAS GENERALLY WELL-TOLERATED;
OBJECTIVE
RESPONSES OBSERVED ACROSS MULTIPLE TUMOR TYPES
    * XENCOR INC - ADDITIONAL COMPLETE RESPONSE OBSERVED IN
PATIENT
WITH ADVANCED BRCA1+ HIGH-GRADE SEROUS OVARIAN CANCER

Source text for Eikon:  ID:nBw7fLv7Da 
Further company coverage:  XNCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))